Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ceralasertib · AZD-6738

Small molecule · Inhibitor of ATR · developed by ASTRAZENECA

Phase 1 Most advanced trial

AZN Developer

1 Registered trials

What is Ceralasertib?

Ceralasertib is an orally available ATR kinase inhibitor that blocks downstream phosphorylation of CHK1, preventing ATR-mediated signaling and disrupting DNA damage repair. It induces tumor cell apoptosis and sensitizes cells to chemotherapy and radiotherapy. It is studied in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD-6738
Drug type: Small molecule
Targets: ATR, CHK1 (CHEK1) (secondary target)
Mechanism: Inhibitor of ATR
Pathways: DNA damage checkpoint, DNA damage repair, cell cycle progression
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 85RE35306Z

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03770429	Phase 1	Leukemia	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

LeukemiaMyelodysplastic Syndrome

Other drugs acting on ATR

ATRN-119 Phase 1/2 IMP9064 Investigational

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Ceralasertib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z